Evista (raloxifene), the new designer estrogen

    You're going to hear a lot about Evista (raloxifene), the new "designer estrogen" from Lilly.

    It's INITIALLY approved just to prevent osteoporosis.

    But Evista and future designer estrogens will revolutionize hormone replacement therapy because they're more selective. They mimic the effects of estrogen in SOME tissues...but not others.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote